Evolution of the Average Target: AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

290e.gx20kxgUdg28aXIgU6ul2ZfVQGW06Ob-8s5r1fhTGlo.sHnx2HFfGW7IAUYXAcP36PWdIzGNioWxoZkt7J0fSh27VtzKW1w9SfITJw~20daefe9a5b1303065454d3192c26278
09-18 Berenberg and Deutsche say buy Bytes Technology AN
09-16 AstraZeneca PLC : Gets a Buy rating from UBS ZD
09-16 Oddo BHF cuts Safestore to neutral, cuts target AN
09-16 AstraZeneca PLC : Buy rating from Jefferies ZD
09-16 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
09-16 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
09-15 Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says MT
09-15 Deutsche Bank Upgrades AstraZeneca to Hold, Lifts PT MT
09-15 Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating MT
09-15 Berenberg Maintains AstraZeneca at Buy as Pipeline Success Offsets Recent Setbacks; Price Target Down MT
09-15 Berenberg likes GSK; Deutsche Bank lifts Astra AN
09-15 AstraZeneca PLC : Berenberg keeps its Buy rating ZD
09-15 AstraZeneca PLC : Deutsche Bank withdraws its Sell rating ZD
09-14 AstraZeneca PLC : JP Morgan reiterates its Buy rating ZD
09-14 AstraZeneca PLC : Jefferies reiterates its Buy rating ZD
09-10 Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained MT
09-10 AstraZeneca PLC : Gets a Sell rating from Deutsche Bank ZD
09-10 AstraZeneca PLC : Berenberg reiterates its Buy rating ZD
09-09 RBC Capital Markets Initiates AstraZeneca Coverage at Outperform MT
09-09 RBC Initiates AstraZeneca at Outperform With GBP145 Price Target MT
09-09 RBC prefers Astra to GSK; HSBC cuts Burberry AN
09-09 RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point MT
09-08 AstraZeneca PLC : Gets a Buy rating from RBC ZD
09-08 AstraZeneca PLC : Buy rating from JP Morgan ZD
09-08 AstraZeneca PLC : Receives a Sell rating from Deutsche Bank ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.14%
+2.67%
+5.09%
+3.29%
+6.25%
- +28.98%
-4.14%
+5.99%
+21.56%
Average +9.09%
Weighted average by Cap. +8.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.19USD
Average target price
211.41USD
Spread / Average Target
+27.21%
High Price Target
273.17USD
Spread / Highest target
+64.37%
Low Price Target
157.72USD
Spread / Lowest Target
-5.10%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-